JENBURPH: H1 revenue advanced, but PAT and EPS declined year over year

What happened

Jenburkt Pharmaceuticals reported Q2 revenue of ₹4,831.82 lakh and profit after tax (PAT) of ₹1,020.94 lakh. First-half revenue rose versus the prior year, but first-half PAT and earnings per share (EPS) declined, and operating cash flow was ₹1,719.22 lakh.

Confirmed

Global impact / market context

Revenue growing while profit and earnings per share fall means more sales are not turning into more profit, so costs likely rose or profit per sale shrank. For investors, weaker profit despite higher sales can pressure the shares even as the top line grows.

Analyst inference

The first-half cash flow shows the business still generated cash available from operations, which supports its ability to fund daily costs and capital spending. The key question is whether the profit decline is temporary or a lasting squeeze on profit per sale.

Analyst inference

What to watch

1. Watch whether first-half profit after tax and earnings per share keep declining, since both fell versus the prior year while revenue rose. Confirmed
2. Monitor management commentary on what pushed costs up, because higher costs would explain weaker profit despite growing first-half revenue. Proposed
3. Track whether operating cash flow of ₹1,719.22 lakh holds up, since weaker cash generation could limit the company's ability to fund capital spending. Analyst inference

Evidence

• Original source link unavailable